Edition:
United Kingdom

INSYS Therapeutics Inc (INSY.OQ)

INSY.OQ on NASDAQ Stock Exchange Global Market

8.00USD
6:16pm BST
Change (% chg)

$0.13 (+1.65%)
Prev Close
$7.87
Open
$7.95
Day's High
$8.12
Day's Low
$7.90
Volume
89,765
Avg. Vol
132,513
52-wk High
$14.00
52-wk Low
$4.10

Latest Key Developments (Source: Significant Developments)

Insys Therapeutics Responds To Unsealing Of Previously Filed Qui Tam Complaints
Tuesday, 15 May 2018 

May 15 (Reuters) - INSYS Therapeutics Inc ::INSYS THERAPEUTICS RESPONDS TO UNSEALING OF PREVIOUSLY FILED QUI TAM COMPLAINTS AND RECAPS TRANSFORMATION EFFORTS.INSYS THERAPEUTICS - ONGOING DIALOGUE WITH DOJ HAS NOT RESULTED IN INFORMATION THAT WOULD CAUSE CO TO REVISE ESTIMATE OF MINIMUM LIABILITY EXPOSURE.INSYS THERAPEUTICS SAYS CONTINUES TO HAVE ONGOING DIALOGUE WITH U.S. DOJ REGARDING INVESTIGATION THAT IN DEC 2013 WAS COMMENCED BY DOJ'S CIVIL DIVISION.  Full Article

Insys Therapeutics Announces Exclusive License Partnership To Commercialize Subsys In Middle East
Tuesday, 8 May 2018 

May 8 (Reuters) - INSYS Therapeutics Inc ::INSYS THERAPEUTICS ANNOUNCES EXCLUSIVE LICENSE PARTNERSHIP WITH LUNATUS TO COMMERCIALIZE SUBSYS® (FENTANYL SUBLINGUAL SPRAY) IN THE MIDDLE EAST.INSYS - CO'S RESPONSIBILITIES WILL INCLUDE SUPPLYING SUBSYS TO LUNATUS, WHOSE RESPONSIBILITIES WILL INCLUDE OBTAINING APPROVALS TO COMMERCIALIZE SUBSYS.INSYS - LUNATUS WILL BE EXCLUSIVE LICENSEE FOR SUBSYS IN BAHRAIN, JORDAN, KUWAIT, LEBANON, OMAN, QATAR, SAUDI ARABIA AND UNITED ARAB EMIRATES.  Full Article

Insys' Treatment For Prader-Willi Syndrome Gets ‘Fast Track’ Designation
Tuesday, 26 Dec 2017 

Dec 26 (Reuters) - Insys Therapeutics Inc ::FDA GRANTS INSYS THERAPEUTICS ‘FAST TRACK’ DESIGNATION FOR CANNABIDIOL (CBD) ORAL SOLUTION AS INVESTIGATIONAL TREATMENT FOR PRADER-WILLI SYNDROME.INSYS THERAPEUTICS - PLAN TO START CLINICAL DEVELOPMENT PROGRAM FOR CANNABIDIOL ORAL SOLUTION IN LATE Q1 OF 2018.  Full Article

Insys Therapeutics Inc - ‍Study Is Expected To Be Completed In Late 2018 For Of Cbd Oral Solution-A​
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Insys Therapeutics Inc ::INSYS THERAPEUTICS INITIATES PHASE 2 CLINICAL TRIAL OF CANNABIDIOL (CBD) ORAL SOLUTION FOR TREATMENT OF REFRACTORY CHILDHOOD ABSENCE EPILEPSY IN PEDIATRIC PATIENTS.INSYS THERAPEUTICS INC - ‍STUDY IS EXPECTED TO BE COMPLETED IN LATE 2018 FOR OF CBD ORAL SOLUTION-A​.  Full Article

Insys Therapeutics' NDA For Buprenorphine Sublingual Spray Accepted By FDA
Wednesday, 6 Dec 2017 

Dec 6 (Reuters) - Insys Therapeutics Inc ::FDA ACCEPTS NEW DRUG APPLICATION (NDA) FOR BUPRENORPHINE SUBLINGUAL SPRAY FROM INSYS THERAPEUTICS.SAYS ‍UNDER PDUFA, FDA HAS SET TARGET DATE OF JULY 28, 2018 TO COMPLETE REVIEW OF NDA FOR BUPRENORPHINE SUBLINGUAL SPRAY​.SAYS ‍DATA FROM RECENTLY COMPLETED 7-DAY SAFETY & TOLERABILITY STUDY TO BE SUBMITTED TO FDA IN Q1 2018, MAY IMPACT PDUFA DATE​.  Full Article

Insys Therapeutics reports Q3 loss per share of $2.30
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Insys Therapeutics Inc :Insys therapeutics reports third quarter 2017 results.Q3 loss per share $2.30.Q3 revenue $48.9 million.Q3 revenue view $35.5 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S.Insys therapeutics inc qtrly ‍net revenue was unfavorably impacted by approximately $5 million due to product returns​.Insys therapeutics inc qtrly ‍ gross revenue was $48.9 million, resulting in net revenue of $30.7 million​.  Full Article

Insys Therapeutics provides update on NASDAQ trading hold
Monday, 30 Oct 2017 

Oct 30 (Reuters) - Insys Therapeutics Inc ::Insys Therapeutics provides update on NASDAQ trading hold.Subsequent to trading hold placed on stock on Thursday after market close, received series of questions on Friday from NASDAQ​.Questions received from NASDAQ on Oct 27 have been addressed, co is awaiting response from NASDAQ regarding resumption of trading​.  Full Article

Insys Therapeutics reports preliminary estimated revenues from Subsys for Q3 2016 to be $54 mln -$55 mln
Thursday, 13 Oct 2016 

Insys Therapeutics Inc : Insys Therapeutics reports preliminary estimated revenues from subsys for the third quarter 2016 . Insys Therapeutics Inc - preliminary estimated revenues from Subsys (fentanyl sublingual spray) for Q3 of 2016 will be in range of $54 million to $55 million . Insys Therapeutics Inc- company believes it will be cash-flow positive at the level of sales . Insys Therapeutics Inc - "estimated revenues for quarter reflect a decline in prescriptions" .Insys Therapeutics-believes scrutiny resulted in patients having difficulty getting reimbursement for transmucosal immediate release fentanyl medications.  Full Article

Insys Therapeutics Q2 earnings per share $0.06
Wednesday, 3 Aug 2016 

Insys Therapeutics Inc : Q2 adjusted non-gaap earnings per share $0.13 . Q2 revenue $67.1 million versus i/b/e/s view $66.9 million . Insys therapeutics reports second quarter 2016 results . Q2 earnings per share $0.06 .Q2 earnings per share view $0.07 -- Thomson Reuters I/B/E/S.  Full Article

Insys Therapeutics announces FDA approval of Syndros
Tuesday, 5 Jul 2016 

Insys Therapeutics Inc : Syndros is currently awaiting scheduling by U.S. Drug Enforcement Administration . Company anticipates launching Syndros in second half of 2016 . Syndros is approved for use in treating anorexia associated with weight loss in patients with AIDS . Insys therapeutics announces FDA approval of Syndros .Syndros is also approved for use in treating nausea, vomiting associated cancer chemotherapy in patients.  Full Article

Florida doctor admits taking kickbacks from Insys, others

June 4 A Florida doctor has admitted, as part of a plea deal, that he received kickbacks from Insys Therapeutics Inc in exchange for writing prescriptions for a powerful fentanyl-based pain medicine.